Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Verinurad. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 known ✓ | Q96S37 | 20/20 | 1.00 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 1.00 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Verinurad SCHEMBL29362845 | 1.00 | SLC22A12 (1.00) | SLC22A12SLC22A6SLC22A11ABCG2 | |
| Verinurad SCHEMBL18979018 | 0.94 | SLC22A12 (0.88) | SLC22A12SLC22A6SLC22A11ABCG2 | |
| Verinurad SCHEMBL30109019 | 0.93 | SLC22A12 (0.86) | SLC22A12SLC22A6SLC22A11ABCG2 | |
| Verinurad SCHEMBL20587211 | 0.93 | SLC22A12 (0.86) | SLC22A12SLC22A6SLC22A11ABCG2 | |
| Verinurad SCHEMBL18979101 | 0.92 | SLC22A12 (0.86) | SLC22A12SLC22A6SLC22A11ABCG2 | |
| SCHEMBL15164011 | 0.91 | SLC22A12 (0.83) | SLC22A12SLC22A6SLC22A11ABCG2 | |
| Verinurad SCHEMBL21828465 | 0.89 | SLC22A12 (1.00) | SLC22A12SLC22A6SLC22A11ABCG2 | |
| SCHEMBL15165680 | 0.88 | SLC22A12 (0.78) | SLC22A12SLC22A6SLC22A11ABCG2 | |
| SCHEMBL20020019 | 0.88 | SLC22A12 (0.78) | SLC22A12SLC22A6SLC22A11ABCG2 | |
| SCHEMBL12070799 | 0.86 | SLC22A12 (1.00) | SLC22A12SLC22A6SLC22A11ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230011269-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A POTENT INHIBITOR OF URAT1 | ASTRAZENECA AB (SE) | 2023-01-12 | — | — | US | claimed |
| US-20210113472-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A POTENT INHIBITOR OF URAT1 | ARDEA BIOSCIENCES, INC. | 2021-04-22 | — | — | US | claimed |
| US-10570095-B2 | 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same | ARDEA BIOSCIENCES, INC. (US) | 2020-02-25 | — | — | US | claimed |
| EP-3501520-A1 | 3,4-DI-SUBSTITUTED PYRIDINE COMPOUND, METHODS OF USING AND COMPOSITIONS COMPRISING THE SAME | Ardea Biosciences, Inc. (US) | 2019-06-26 | — | — | EP | claimed |
| US-20190135756-A1 | 3,4-DI-SUBSTITUTED PYRIDINE COMPOUND, METHODS OF USING AND COMPOSITIONS COMPRISING THE SAME | ARDEA BIOSCIENCES, INC. | 2019-05-09 | — | — | US | claimed |
| US-20180360761-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A POTENT INHIBITOR OF URAT1 | ARDEA BIOSCIENCES, INC. (US) | 2018-12-20 | — | — | US | claimed |
| EP-3386485-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A POTENT INHIBITOR OF URAT1 | Ardea Biosciences, Inc. (US) | 2018-10-17 | — | — | EP | claimed |
| EP-2776028-B1 | 3,4-DI-SUBSTITUTED PYRIDINE COMPOUND, METHODS OF USING AND COMPOSITIONS COMPRISING THE SAME | ARDEA BIOSCIENCES INC (US) | 2018-10-17 | — | — | EP | claimed |
| WO-2017097845-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A POTENT INHIBITOR OF URAT1 | ARDEA BIOSCIENCES, INC. (US) | 2017-06-15 | — | — | WO | claimed |
| EP-2712861-B1 | Thioacetate compounds, compositions and methods of use | ARDEA BIOSCIENCES INC (US) | 2015-07-29 | — | — | EP | claimed |
| EP-2776028-A1 | 3,4-DI-SUBSTITUTED PYRIDINE COMPOUND, METHODS OF USING AND COMPOSITIONS COMPRISING THE SAME | Ardea Biosciences, Inc. (US) | 2014-09-17 | — | — | EP | claimed |
| US-20140256748-A1 | 3,4-DI-SUBSTITUTED PYRIDINE COMPOUND, METHODS OF USING AND COMPOSITIONS COMPRISING THE SAME | ARDEA BIOSCIENCES INC. | 2014-09-11 | — | — | US | claimed |
| WO-2013067425-A1 | 3,4-DI-SUBSTITUTED PYRIDINE COMPOUND, METHODS OF USING AND COMPOSITIONS COMPRISING THE SAME | ARDEA BIOSCIENCES INC. (US) | 2013-05-10 | — | — | WO | claimed |
| US-20230037277-A9 | DOSE DUMPING RESISTANT PHARMACEUTICAL COMPOSITIONS COMPRISING VERINURAD | ASTRAZENECA AB (SE) | 2023-02-02 | — | — | US | disclosed |
| US-20230037277-A9 | DOSE DUMPING RESISTANT PHARMACEUTICAL COMPOSITIONS COMPRISING VERINURAD | ASTRAZENECA AB (SE) | 2023-02-02 | — | — | US | disclosed |
| US-20230011269-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A POTENT INHIBITOR OF URAT1 | ASTRAZENECA AB (SE) | 2023-01-12 | — | — | US | disclosed |
| US-20130202573-A1 | THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| WO-2013067425-A1 | 3,4-DI-SUBSTITUTED PYRIDINE COMPOUND, METHODS OF USING AND COMPOSITIONS COMPRISING THE SAME | ARDEA BIOSCIENCES INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013067425-A1 | 3,4-DI-SUBSTITUTED PYRIDINE COMPOUND, METHODS OF USING AND COMPOSITIONS COMPRISING THE SAME | ARDEA BIOSCIENCES INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| WO-2011159839-A2 | THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130202573-A1 | THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | TXN, TXN2, XDH | SLC22A12 757/4885SLC22A6 477/4885SLC22A11 594/4885 |
| US-20180360761-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A POTENT INHIBITOR OF URAT1 | UGP2, MPST, SLC10A1 | SLC22A12 256/4885SLC22A6 228/4885SLC22A11 227/4885 |
| US-20230011269-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A POTENT INHIBITOR OF URAT1 | UGP2, MPST, SLC10A1 | SLC22A12 256/4885SLC22A6 228/4885SLC22A11 227/4885 |
| US-10570095-B2 | 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same | PLPBP, XDH, TPMT | SLC22A12 603/4885SLC22A6 284/4885SLC22A11 530/4885 |
| US-20190135756-A1 | 3,4-DI-SUBSTITUTED PYRIDINE COMPOUND, METHODS OF USING AND COMPOSITIONS COMPRISING THE SAME | PLPBP, XDH, TPMT | SLC22A12 603/4885SLC22A6 284/4885SLC22A11 530/4885 |
| US-20230037277-A9 | DOSE DUMPING RESISTANT PHARMACEUTICAL COMPOSITIONS COMPRISING VERINURAD | CEL, PNLIP, SLC10A2 | SLC22A12 1218/4885SLC22A6 405/4885SLC22A11 723/4885 |
| US-20210113472-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A POTENT INHIBITOR OF URAT1 | UGP2, MPST, SLC14A1 | SLC22A12 246/4885SLC22A6 235/4885SLC22A11 216/4885 |
| US-20140256748-A1 | 3,4-DI-SUBSTITUTED PYRIDINE COMPOUND, METHODS OF USING AND COMPOSITIONS COMPRISING THE SAME | TPMT, PLPBP, XDH | SLC22A12 542/4885SLC22A6 276/4885SLC22A11 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.